Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 6/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.44 |
| ▸ | HPGD | P15428 | 8/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20151840 | 0.86 | TSHR (0.48) | MAPTMEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL21821059 | 0.86 | CYP1A2 (0.44) | MAPTMEN1KMT2ACYP1A2KDM4E | |
| SCHEMBL25470720 | 0.85 | PTGDR2 (0.45) | MAPTKMT2AHPGDSMN1; SMN2RAB9A | |
| SCHEMBL20137041 | 0.83 | RXRA (0.38) | MAPTKMT2AHPGDSMN1; SMN2CYP1A2 | |
| SCHEMBL20182410 | 0.83 | MAPT (0.48) | MAPTMEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL23087387 | 0.81 | PTGDR2 (0.43) | MEN1KMT2AHPGDRAB9ACYP1A2 | |
| SCHEMBL25470728 | 0.81 | PTGDR2 (0.43) | MEN1KMT2AHPGDRAB9ACYP1A2 | |
| SCHEMBL22114187 | 0.81 | IDO1 (0.50) | MAPTMEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL23087373 | 0.81 | PTGDR2 (0.43) | MEN1KMT2AHPGDRAB9ACYP1A2 | |
| SCHEMBL20182409 | 0.80 | MAPT (0.45) | MAPTMEN1KMT2AHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541820-B1 | MAGL INHIBITORS | H LUNDBECK AS (DK) | 2023-07-05 | — | — | EP | disclosed |
| EP-3541820-B1 | MAGL INHIBITORS | H LUNDBECK AS (DK) | 2023-07-05 | — | — | EP | disclosed |
| US-11691975-B2 | MAGL inhibitors | H. LUNDBECKA/S (DK) | 2023-07-04 | — | — | US | disclosed |
| US-11691975-B2 | MAGL inhibitors | H. LUNDBECKA/S (DK) | 2023-07-04 | — | — | US | disclosed |
| US-11691975-B2 | MAGL inhibitors | H. LUNDBECKA/S (DK) | 2023-07-04 | — | — | US | disclosed |
| US-20220135563-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-05-05 | — | — | US | disclosed |
| US-20220135563-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-05-05 | — | — | US | disclosed |
| CN-110267962-B | MAGL inhibitors | H.隆德贝克有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-11059822-B2 | MAGL inhibitors | H. LUNDBECK A/S (DK) | 2021-07-13 | — | — | US | disclosed |
| US-11059822-B2 | MAGL inhibitors | H. LUNDBECK A/S (DK) | 2021-07-13 | — | — | US | disclosed |
| US-20200291023-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2020-09-17 | — | — | US | disclosed |
| US-20200291023-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2020-09-17 | — | — | US | disclosed |
| EP-3541820-A1 | MAGL INHIBITORS | Abide Therapeutics, Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018093949-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018093949-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059822-B2 | MAGL inhibitors | MAG, MAGI3, MGLL | MAPT 1616/4885MEN1 2023/4885KMT2A 2533/4885 |
| US-20220135563-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | MAPT 1616/4885MEN1 2023/4885KMT2A 2533/4885 |
| US-20200291023-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | MAPT 1616/4885MEN1 2023/4885KMT2A 2533/4885 |
| US-11691975-B2 | MAGL inhibitors | MAG, MAGI3, MGLL | MAPT 1616/4885MEN1 2023/4885KMT2A 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.